ARROWHEAD PHARMACEUTICALS, INC. Financing Cash Flow
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Financing Cash Flow of $780.52 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$449.00K.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $795.72M, a 761.33% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$14.75M, a 171.48% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.67M, a 99.06% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $74.01M, a 91.50% decline from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $870.52M, a 244.01% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $253.05M, a 288.20% increase from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $65.19M, a 476.61% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$449.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $795.27M derived: sum of 2 quarters · filed 2026-08-04 | $780.52M 10-Q · filed 2026-08-04 | $784.19M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $795.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $780.97M 10-Q · filed 2026-05-07 | $784.64M derived: sum of 3 quarters · filed 2026-05-07 | $741.96M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$14.75M 10-Q · filed 2026-02-05 | -$11.08M derived: sum of 2 quarters · filed 2026-02-05 | -$53.76M derived: sum of 3 quarters · filed 2026-08-04 | $38.62M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-09-30 | $3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$39.01M derived: sum of 2 quarters · filed 2026-08-04 | $53.37M derived: sum of 3 quarters · filed 2026-08-04 | $74.01M 10-K · filed 2025-11-25 | ||||
| 2025-06-30 | -$42.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $49.70M derived: sum of 2 quarters · filed 2026-08-04 | $70.34M 10-Q · filed 2026-08-04 | $459.43M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $92.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $113.02M 10-Q · filed 2026-05-07 | $502.11M derived: sum of 3 quarters · filed 2026-05-07 | $552.49M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $20.63M 10-Q · filed 2026-02-05 | $409.72M derived: sum of 2 quarters · filed 2026-02-05 | $460.11M derived: sum of 3 quarters · filed 2026-02-05 | $890.89M derived: sum of 4 quarters · filed 2026-02-05 | ||||
| 2024-09-30 | $389.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $439.48M derived: sum of 2 quarters · filed 2025-11-25 | $870.25M derived: sum of 3 quarters · filed 2025-11-25 | $870.52M 10-K · filed 2025-11-25 | ||||
| 2024-06-30 | $50.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | $481.16M derived: sum of 2 quarters · filed 2025-08-07 | $481.43M 10-Q · filed 2025-08-07 | $482.25M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2024-03-31 | $430.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | $431.04M 10-Q · filed 2025-05-12 | $431.87M derived: sum of 3 quarters · filed 2025-11-25 | $433.00M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2023-12-31 | $267.00K 10-Q · filed 2025-02-10 | $1.09M derived: sum of 2 quarters · filed 2025-11-25 | $2.22M derived: sum of 3 quarters · filed 2025-11-25 | $2.74M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2023-09-30 | $821.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $1.96M derived: sum of 2 quarters · filed 2025-11-25 | $2.48M derived: sum of 3 quarters · filed 2025-11-25 | $253.05M 10-K · filed 2025-11-25 | ||||
| 2023-06-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | $1.66M derived: sum of 2 quarters · filed 2024-08-08 | $252.23M 10-Q · filed 2024-08-08 | $252.90M 10-Q · filed 2023-08-07 | $253.09M derived: sum of 4 quarters · filed 2024-11-26 | |||
| 2023-03-31 | $520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | $251.10M 10-Q · filed 2024-05-09 | $251.95M derived: sum of 3 quarters · filed 2024-11-26 | $312.55M derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-12-31 | $250.58M 10-Q · filed 2024-02-06 | $251.43M derived: sum of 2 quarters · filed 2024-11-26 | $312.03M derived: sum of 3 quarters · filed 2024-11-26 | $313.88M derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-09-30 | $855.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $61.45M derived: sum of 2 quarters · filed 2024-11-26 | $63.30M derived: sum of 3 quarters · filed 2024-11-26 | $65.19M 10-K · filed 2024-11-26 | ||||
| 2022-06-30 | $60.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $62.45M derived: sum of 2 quarters · filed 2023-08-07 | $64.33M 10-Q · filed 2023-08-07 | $65.15M derived: sum of 4 quarters · filed 2023-11-29 | ||||
| 2022-03-31 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | $3.73M 10-Q · filed 2023-05-02 | $4.55M derived: sum of 3 quarters · filed 2023-11-29 | $7.30M derived: sum of 4 quarters · filed 2023-11-29 | ||||
| 2021-12-31 | $1.89M 10-Q · filed 2023-02-06 | $2.70M derived: sum of 2 quarters · filed 2023-11-29 | $5.46M derived: sum of 3 quarters · filed 2023-11-29 | $8.09M derived: sum of 4 quarters · filed 2023-11-29 | ||||
| 2021-09-30 | $815.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $3.57M derived: sum of 2 quarters · filed 2023-11-29 | $6.20M derived: sum of 3 quarters · filed 2023-11-29 | $11.30M 10-K · filed 2023-11-29 | ||||
| 2021-06-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-04 | $5.39M derived: sum of 2 quarters · filed 2022-08-04 | $10.49M 10-Q · filed 2022-08-04 | $11.49M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2021-03-31 | $2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-10 | $7.74M 10-Q · filed 2022-05-10 | $8.74M derived: sum of 3 quarters · filed 2022-11-28 | $10.87M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2020-12-31 | $5.10M 10-Q · filed 2022-02-02 | $6.11M derived: sum of 2 quarters · filed 2022-11-28 | $8.24M derived: sum of 3 quarters · filed 2022-11-28 | $9.57M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2020-09-30 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $3.14M derived: sum of 2 quarters · filed 2022-11-28 | $4.47M derived: sum of 3 quarters · filed 2022-11-28 | $257.95M 10-K · filed 2022-11-28 | $257.95M 10-K · filed 2020-11-23 | |||
| 2020-06-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-05 | $3.46M derived: sum of 2 quarters · filed 2021-08-05 | $256.94M 10-Q · filed 2021-08-05 | $256.94M 10-Q · filed 2020-08-05 | $258.78M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2020-03-31 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-04 | $254.81M 10-Q · filed 2021-05-04 | $254.81M 10-Q · filed 2020-05-07 | $256.64M derived: sum of 3 quarters · filed 2021-11-22 | $259.41M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2019-12-31 | $253.48M 10-Q · filed 2021-02-04 | $253.48M 10-Q · filed 2020-02-05 | $255.31M derived: sum of 2 quarters · filed 2021-11-22 | $258.08M derived: sum of 3 quarters · filed 2021-11-22 | $260.75M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2019-09-30 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22 | $4.60M derived: sum of 2 quarters · filed 2021-11-22 | $7.27M derived: sum of 3 quarters · filed 2021-11-22 | $66.38M 10-K · filed 2021-11-22 | $66.38M 10-K · filed 2019-11-25 | |||
| 2019-06-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | $5.44M derived: sum of 2 quarters · filed 2020-08-05 | $64.55M 10-Q · filed 2020-08-05 | $66.12M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2019-03-31 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07 | $61.78M 10-Q · filed 2020-05-07 | $63.35M derived: sum of 3 quarters · filed 2020-11-23 | $64.81M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2018-12-31 | $59.11M 10-Q · filed 2020-02-05 | $60.68M derived: sum of 2 quarters · filed 2020-11-23 | $62.14M derived: sum of 3 quarters · filed 2020-11-23 | $119.04M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2018-09-30 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-23 | $3.03M derived: sum of 2 quarters · filed 2020-11-23 | $59.93M derived: sum of 3 quarters · filed 2020-11-23 | $59.95M 10-K · filed 2020-11-23 | ||||
| 2018-06-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-05 | $58.36M derived: sum of 2 quarters · filed 2019-08-05 | $58.38M 10-Q · filed 2019-08-05 | $58.26M derived: sum of 4 quarters · filed 2019-11-25 | ||||
| 2018-03-31 | $56.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-08 | $56.93M 10-Q · filed 2019-05-08 | $56.81M derived: sum of 3 quarters · filed 2019-11-25 | |||||
| 2017-12-31 | $26.29K 10-Q · filed 2019-02-07 | -$96.05K derived: sum of 2 quarters · filed 2019-11-25 | ||||||
| 2017-09-30 | -$122.34K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $12.06M 10-K · filed 2019-11-25 | ||||||
| 2017-06-30 | $12.18M 10-Q · filed 2018-08-07 | |||||||
| 2016-09-30 | $55.13M 10-K · filed 2018-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |